MALVERN, PA — Endo, Inc. (OTCQX: NDOI) has announced a significant leadership change as Blaise Coleman steps down from his roles as President, CEO, and Board member, effective August 29, 2024. The Board of Directors has engaged Spencer Stuart, a renowned executive search firm, to assist in selecting the company’s next Chief Executive Officer.
Scott Hirsch has been appointed as Interim CEO to steer the company during this transitional phase. Hirsch, who joined Endo’s Board in April 2024, brings over 20 years of expertise in healthcare and financial services. His previous leadership at Solta Medical saw the company through a successful expansion, and he has also helmed key segments at Bausch Health/Bausch & Lomb.
Paul Herendeen, Chairman of the Board, stated, “Following the completion of our reorganization, Endo is strategically well-positioned to become a vibrant growth company with a strong balance sheet, a broad, diversified portfolio of on-market medicines, and a pipeline of innovative and differentiated product candidates. As we work toward our goal of re-listing on a national stock exchange, the Board is focused on identifying a new chief executive with the experience, skill set and strategic vision to guide Endo through its next phase of development.”
Scott Hirsch expressed his commitment to maintaining the company’s momentum, saying, “I’d like to thank Blaise for his many contributions to Endo and wish him well in his future endeavors. In the near term, our priority will be continued focus on execution across our branded, sterile injectables, and generics portfolios as we position the Company for long-term growth.”
Endo aims to leverage this leadership transition to enhance its strategic focus and drive sustained growth.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.